Calliditas Therapeutics AB (publ) (NASDAQ:CALT) Q4 2023 Earnings Call Transcript

Suzanne van Voorthuizen: Got it. All right. And then maybe on Europe, can you provide some color on what the sales development look like for Kinpeygo? And what was the 2023 sales into the year?

Renee Aguiar-Lucander: So I think we have kind of royalty numbers, but I don’t know if we have anything Fredrik, what would be on a kind of…

Fredrik Johansson: Yes, we have the royalty number, which we separate in our reporting. And overall, for the full year, we reported approximately SEK40 million in royalties for you.

Renee Aguiar-Lucander: Yeah. And so actually, they don’t — STADA is obviously a very large company. They don’t necessarily break this out or kind of disclose any of these details. So therefore, we don’t really have access to those type of numbers. But obviously, we are aware of the fact that the — they are gaining kind of approval and acceptances from a variety of European countries, UK obviously being the most recent one. And it’s my understanding that they’re in kind of negotiations with at least four other geographic regions in Europe with a hope to obviously reach a conclusion there also fairly shortly. But that is the kind of insight that I have this time.

Suzanne van Voorthuizen: All right. Thank you.

Operator: There are no more questions at this time. So I hand the conference back to the speakers for any closing comments.

Renee Aguiar-Lucander: Thank you very much, and thank you very much for listening to this Q4 report from 2023, and we look forward to meeting you again and when we get to report our Q1, which is due in May of this year. Thank you very much.